Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: A phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group
| Title: | Salvage treatment for primary resistant acute myelogenous leukemia consisting of intermediate-dose cytosine arabinoside and interspaced continuous infusions of idarubicin: A phase-II study (no. 06901) of the EORTC Leukemia Cooperative Group |
|---|---|
| Authors: | Witte, T. De; Suciu, S.; Selleslag, D.; Labar, B.; Roozendaal, K.; Zittoun, R.; Ribeiro, M.; Kurstjens, R.; Hayat, M.; Dardenne, M.; Solbu, G.; Muus, P. |
| Source: | Annals of Hematology. March 1996 72(3):119-124 |
| Database: | Springer Nature Journals |